Arcellx iMMagine-1 study: 97% ORR, 62% CR/sCR, no delayed neurotoxicity in RRMM

Arcellx, Inc.

Phase 2 pivotal iMMagine-1: 86 patients evaluable; ORR 97% (83/86), CR/sCR 62% (53/86) at median 9.5-month follow-up.
No delayed neurotoxicities (Parkinsonism, cranial nerve palsies, Guillain-Barré) in >150 dosed patients across Phase 1 and iMMagine-1.
Phase 1 study shows 30.2-month median PFS at 38.1 months follow-up; median OS not reached.
MRD negativity achieved in 93.1% (54/58) evaluable at ≥10⁻⁵ sensitivity.
Safety: 86% had Grade ≤1 CRS; 91% had no ICANS; most common Grade ≥3 TEAE was neutropenia (54%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.